The Multidisciplinary NET Medical Symposium - October 3-5, 2019

Over 400 medical professionals gather in Boston for three days of multidisciplinary, accredited, medical education on the latest in diagnosis, treatment and management of NET disease.

The 2019 Multidisciplinary NET Medical Symposium, October 3-5, 2019, provides a forum for members of the professional neuroendocrine community to come together to discuss new diagnostic and therapeutic techniques, optimal multidisciplinary care, and the future of neuroendocrine tumor research. NANETS NET disease educational programming is designed exclusively for medical professionals, by leading medical professionals in the field. Register here.

Neuroendocrine tumor (NET) disease is both rare and complex. About 15,000 new patients are diagnosed each year in the U.S. – which means many medical professionals will encounter neuroendocrine tumors only a few times in their careers.

The North American Neuroendocrine Tumor Society (NANETS) is a society of over 400 multidisciplinary medical professionals committed to the support of colleagues in diagnosing and treating NET patients, as well as furthering the cause of NET science and education in North America. With new research, technologies and practices emerging, the landscape of NET treatment is rapidly changing.

We invite you to the 2019 Symposium in Boston from October 3–5, the premier opportunity to share in the growing knowledge of NET disease treatment and to interact with your medical peers on the front lines of the disease. Over the course of three days, participants will be privy to the latest in NET research, diagnostic techniques, treatment options and best patient practices. 

In addition to continuing education accredited sessions, this symposium includes presentations on cutting-edge NET research in interactive sessions and two days of poster sessions, young investigator presentations, early career track and comprehensive allied health track. NANETS' annual grant awards are announced each year at this symposium. Lean more here.